The great majority of testicular cancer is cured with chemotherapy and the remaining cases have a high cure rate with transplant. The BEP regimen was proven to have less toxicity and a higher cure rate and therefore, since 1984, has been standard chemotherapy. This case failed on transplant and the question is about salvage therapy.
Patients who are not cured with their initial BEP chemotherapy are usually treated with salvage chemotherapy. Approximately 50% of these testicular cancer patients will subsequently be cured with salvage chemotherapy with tandem transplant of high-dose chemotherapy with peripheral stem cell rescue. Long-term disease-free survival is possible with paclitaxel plus gemcitabine in those who progressed after high-dose chemotherapy, and had not received prior paclitaxel or gemcitabine, according to a recent phase II trial.
There are several reports of cisplatin and epirubicin.